Results 21 to 30 of about 345,011 (339)
Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies
Current Oncology Reports, 2022 The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease.
K. Lundberg, D. Treis, J. Johnsen
semanticscholar +1 more source
BMC Pediatrics, 2022 Background Previously, we had analyzed the prognosis of E2F transcription factors across adult tumor types. However, the expressions and prognosis of E2F transcription factors in pediatric neuroblastoma have not yet been fully studied.
Haiwei Wang +3 more
doaj +1 more source
Nature Communications, 2021 The ability to utilize preclinical models to predict the clinical toxicity of chimeric antigen receptor (CAR) T cells in solid tumors is tenuous, thereby necessitating the development and evaluation of gated systems.
B. Moghimi +9 more
semanticscholar +1 more source
Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors
Cancer Cell International, 2018 Background A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation. Deregulated activity of RTKs in tumors can determine disease progression and therapeutic responses in several types of ...
Sanja Aveic +7 more
doaj +1 more source
Targeting tachykinin receptors in neuroblastoma [PDF]
, 2016 Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%.
Althoff, Kristina +14 more
core +3 more sources
Cancer Research, 2021 The study shows how MYCN increases intracellular iron levels and subsequent GSH pathway activity and demonstrates the antitumor activity of FDA-approved SAS and auranofin in patient-derived xenograft models of MYCN-amplified neuroblastoma.
K. Floros +18 more
semanticscholar +1 more source
Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter [PDF]
, 1967 Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects.
Brunak, Søren +8 more
core +3 more sources
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]
, 2017 Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht +6 more
core +3 more sources
Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours
BMC Cancer, 2019 Background Neuroblastoma (NB) is a paediatric tumour of the sympathetic nervous system. Half of all cases are defined high-risk with an overall survival less than 40% at 5 years from diagnosis.
P. Fusco +13 more
doaj +1 more source
Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation [PDF]
, 2015 Human cell lines are often used to investigate cellular pathways relevant for physiological or pathological processes or to evaluate cell toxicity or protection induced by different compounds, including potential drugs.
Beltramini, Mariano +7 more
core +12 more sources